Category Archives: Ulcerative Colitis

DUBLIN--(BUSINESS WIRE)--The "Global Ulcerative Colitis Market and Competitive Landscape - 2020" report has been added to ResearchAndMarkets.com's offering. This research report provides comprehensive insights into the Ulcerative Colitis pipeline, epidemiology, market valuations, drug sales, market forecast, drug forecasts, and market shares. The research analyzes and forecasts the Ulcerative Colitis market size and drug sales Continue reading →

The market research report is a brilliant, complete, and much-needed resource for companies, stakeholders, and investors interested in the global Ulcerative Colitis Drugs market. It informs readers about key trends and opportunities in the global Ulcerative Colitis Drugs market along with critical market dynamics expected to impact the global market growth. It offers a range of market analysis studies, including production and consumption, sales, industry value chain, competitive landscape, regional growth, and price. Continue reading →

If enacted into law, the measure would also prohibit the export of the toxic compounds, except for products specifically authorized or required to contain PFAS under federal law. The bill was introduced May 14; it has eight co-sponsors, all Democrats: Pricey Harrison, John Autry, Alison Dahle, Susan Fisher, Marcia Morey, Deb Butler, Zack Hawkins and Raymond Smith. There are 5,000 types of PFAS Continue reading →

Eli Lilly and Co Ulcerative Colitis Market Competitive Analysis: Consistent technological developments, surging industrialization, raw material affluence, increasing demand for the Ulcerative Colitis , and rising disposable incomes, soaring product awareness are adding considerable revenue to the market. According to the report, the Ulcerative Colitis market is expected to report a healthy CAGR from 2020 to 2026. Continue reading →

Text size The French biotech company Abivax announced Thursday that it had received clearance from French regulators to begin a 1,000 patient trial of its experimental anti-inflammatory drug ABX464 in Covid-19 patients, sending shares of the company sharply higher. Abivax (ticker: ABVX.France) jumped 32% on the Euronext Paris exchange on Thursday. The stock is down 1.4% this year. Continue reading →

Texas Rangers pitcher Corey Kluber (right) watches teammate Kyle Gibson throw in the bullpen on the day pitchers and catchers reported for spring training at the team's training facility on Tuesday, Feb. 11, 2020, in Surprise, Ariz. In the next two weeks, Major League Baseball and the Players Association will joust, primarily over economic issues, as they try to come up with a plan for restarting the game. Continue reading →

DGAP-News: ABIVAX / Key word(s): Financing 15.05.2020 / 22:34 The issuer is solely responsible for the content of this announcement. 36 million non-dilutive funding from Bpifrance for Abivax' ABX464 Covid-19 Program ****** ****** PARIS, France, May 15, 2020 - 10:30p.m. (CEST) - Abivax SA (Euronext Paris: FR0012333284 - ABVX), a late stage clinical biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, announces today that Bpifrance (Copil, SGPI) approved a 36 million non-dilutive funding (20.1. Continue reading →

Inflammatory bowel disease (IBD) is not one single thing. It's a lifelong autoimmune inflammatory condition of the gastrointestinal tract thatcan lead to hospitalisations, surgery, and a decreased quality of life Continue reading →

Eli Lilly and Co The scope of the Report: The report analyzes the key opportunities, CAGR, and Y-o-Y growth rates to allow readers to understand all the qualitative and quantitative aspects of the Ulcerative Colitis market. A competition analysis is imperative in the Ulcerative Colitis market and the competition landscape serves this objective Continue reading →

COVID-19 pneumonia was not detected in a cohort of Italian patients with inflammatory bowel disease (IBD), according to results of an observational study published in Gastroenterology. A cohort of 522 patients with IBD (11% pediatric patients aged 7-18 years) in Bergamo, Italy between February 19th and March 23rd, 2020 were included in the study. Patients could contact clinicians through a dedicated phone number to report any complications, including symptoms of COVID-19 Continue reading →